详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis.

10| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Guangzhou University of Chinese Medicine, Guangdong Guangzhou, 510006, China. [2]The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Guangzhou, 510378, China. [3]Department of Clinical Laboratory, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120, China.

出处：

DOI：

ISSN：

关键词： ovarian cancer exosome carbohydrate antigen 125 human epididymis protein 4

摘要：

The main diagnostic indicators of ovarian cancer (OC), including carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4), show good sensitivity and poor specificity or vice versa. This study investigated changes in CA125 and HE4 expression and their correlation in serum-derived exosomes of 55 patients with OC (OC group), 33 patients with malignant tumors (non-OC group), and 55 normal controls (NC group). We compared serum and exosomal CA125 and HE4 levels to determine whether their contents in exosomes were elevated. We also compared the diagnostic efficacy of serum HE4, serum CA125, exosomal CA125, and serum HE4+exosomal CA125 in OC using the receiver operating characteristic (ROC) curve. CA125 levels in serum-derived exosomes in all groups significantly increased (P < 0.0001) compared with serum CA125 levels. HE4 was undetected in exosomes. The ROC curve showed the following values: serum CA125: 0.9093 (area), 87.27% (sensitivity), and 90.91% (specificity); serum HE4: 0.9302, 83.64%, and 94.55%; exosomal CA125: 0.9755, 94.55%, and 92.73%; and serum HE4+exosomal CA125: 0.9861, 96.36%, and 92.73%. In conclusion, CA125 can be detected at higher levels in exosomes than in serum, significantly improving OC diagnosis sensitivity. The serum HE4+exosomal CA125 combination significantly improves OC diagnostic efficiency. © The author(s).

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2018]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.3 最新[2023版] 3.4 最新五年平均 3.182 出版当年[2018版] 3.102 出版当年五年平均 3.249 出版前一年[2017版] 3.565 出版后一年[2019版]

第一作者：

第一作者机构： [2]The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Guangzhou, 510378, China.

共同第一作者：

通讯作者：

通讯机构： [1]Guangzhou University of Chinese Medicine, Guangdong Guangzhou, 510006, China. [2]The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Guangzhou, 510378, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Simultaneous quantitation of carbohydrate antigen 125 and carcinoembryonic antigen in human serum via time-resolved fluoroimmunoassay [2]HE4和CA125联合检测在卵巢癌诊断及预后评估中的价值研究 [3]Construction of an exosome-associated miRNA-mRNA regulatory network and validation of FYCO1 and miR-17-5p as potential biomarkers associated with ovarian cancer [4]Immune-and Metabolism-Associated Molecular Classi?cation of Ovarian Cancer [5]CD137+tumor infiltrating lymphocytes predicts ovarian cancer survival [6]The Role of Succinic Acid Metabolism in Ovarian Cancer. [7]刘伟胜教授治疗卵巢癌的临床经验 [8]凝胶电泳微流控芯片提取外泌体及对人血浆外泌体中miRNA-21 的测定 [9]A Multi-constraint Deep Semi-supervised Learning Method for Ovarian Cancer Prognosis Prediction [10]Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.